Get ready for another liquid biopsy company (probably)

The most promising and hotly debated space in cancer diagnostics might be getting that much more crowded.

The Boston biotech VC Third Rock Ventures is about to launch a cancer diagnostics company, STAT’s Kate Sheridan reports. The company, called Thrive Sciences, was vague about its mission in government filings, but its list of directors includes veterans with experience in liquid biopsy.

The idea behind liquid biopsy — detecting cancer by tracking free-floating cells in blood — has for years been attractive to scientists and investors alike. But years of research have yet to pinpoint a definitive application that might justify all the hype.

Read more.